Colgate Palmolive (India) Limited

Valuation risk: PE of 39.98 against near-flat revenue (₹1,434–1,603 Cr over recent 12 quarters) and EPS that peaked at ₹14.52 (Sep 2024) but has since declined to ₹12.61 (Jun 2026). Verify whether the market is pricing in future growth that is not yet visible.

Margin compression trend: OPM peaked at 34.05% in Mar 2025 and has since fallen to 29.74% (Dec 2025) and 30.12% (Jun 2026). Determine whether this reflects input cost pressure, pricing constraints, or product mix shift.

No apparent revenue growth: Standalone revenue is flat or slightly up (Jun 2026 ₹1,603 is +11.8% YoY, but intervening quarters show no consistent acceleration). Verify whether oral care category is mature and organic growth is limited.

Stock performance disconnect: 1-year return of −11.57% despite ROE of 81.59% and zero debt suggests investor skepticism on growth or valuation sustainability.

Regular dividend payments (6 events across 2024–2026) demonstrate strong free cash flow conversion; verify whether payout ratios allow capacity for distribution capex or product innovation.

Operating margin of 30.98% provides buffer against input-cost inflation or product mix pressure; verify whether planned category expansion into adjacencies (skin, hair) could leverage this margin level.

Zero debt (D/E = 0) leaves balance sheet capacity for investment; verify whether capital deployment plans exist to expand beyond oral care or accelerate growth.

Quarterly revenue of ₹1,600+ Cr sustained over recent periods shows resilient core demand; verify whether geographic expansion into tier-2/3 India or new SKU launches could drive incremental volume.